XML 49 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Information With Respect to Stock Options
The below tables presents information with respect to stock options:
(in thousands, except for exercise price)Number of SharesWeighted
Average
Exercise Price		Aggregate
 Intrinsic Value
Outstanding at Outstanding at January 1, 20221,306 $11.95 
Options exercised(135)9.98 
Options canceled/forfeited(142)10.75 
Outstanding at Outstanding at December 31, 20221,029 $12.82 $13,645 
Vested and expected to vest at December 31, 20221,028 $12.82 $13,622 
Total shares exercisable at December 31, 2022937 $12.87 $12,321 
Shares remaining available for future grant2,169 

(in thousands, except for grant date fair value)202220212020
Option expense recorded, in thousands, for the year ended December 31,$5,664 $9,585 $1,386 
Weighted average grant date fair value$— $60.48 $13.82 
Total intrinsic value of stock options exercised, in thousands, for the year ended December 31,$4,000 $6,000 $1,900 
Cash received for options exercised$1,286 $1,156 $675 
Schedule of Assumptions for Fair Value of Options at the Date of the Grant
Issuance date fair value of the Warrant was determined to be $14.3 million based on using the Black-Scholes model with the following assumptions:


Expected term5.0 years
Risk free interest rate0.85 %
Expected volatility53.78 %
Expected dividend yieldNone
Fair value (per warrant)$28.65 
The fair value of options at the date of the grant was estimated using the Black-Scholes model with the following assumptions for the respective period ending December 31:

20212020
Expected option life3.1 years4.4 years
Weighted average risk-free interest rate0.4 %0.4 %
Weighted average expected volatility56.5 %47.6 %
Expected dividend yieldNoneNone
Schedule of Share-based Compensation by Exercise Price Range Stock options outstanding at December 31, 2022 are summarized as follows:
Range of exercise pricesNumber outstanding (in thousands)Weighted average remaining lifeWeighted average exercise price
$0.73 - $35.26
1,029 6.92 years$12.82 
Schedule of Activity With Respect to Non-vested Stock Options
Current year activity with respect to the Company’s non-vested RSAs is as follows:

(in thousands, except weighted average fair value)SharesWeighted average grant-date fair value
Balance at January 1, 202227$25.42 
Vested(27)25.42
Balance at December 31, 20220
The below table presents information with respect to RSA:

(in thousands)202220212020
Service-based RSA$2 $62 $210 
Performance-based RSA147 776 786 
Total stock-based compensation expense related to RSAs$149 $838 $996 
The fair value of RSAs is based on the closing price of the Company’s common stock on the date of grant. The below table presents information with respect to RSAs:

(in thousands, except weighted average grant date fair value)202220212020
Weighted average grant date fair value of RSAs granted during the year$— $22.30 $30.96 
Number of shares released during the year in accordance with the terms of the RSA agreements27 34 112 
Number of RSA shares canceled during the year— 2 5 
Number of above RSA shares canceled which were performance-based— 1 4 
Summary of Restricted Stock Awards Activity
Current year activity with respect to the Company’s non-vested RSUs is as follows:

(in thousands, except weighted average fair value)SharesWeighted Average grant- date fair value
Balance at January 1, 2022418 $34.08 
Granted379 37.90 
Vested(168)28.41 
Canceled/forfeited(117)45.79 
Balance at December 31, 2022512 $35.96 

The below table presents information with respect to RSUs:

(in thousands)202220212020
Service-based RSU$6,775 $3,353 $1,587 
Performance-based RSU836 839 282 
Total stock-based compensation expense related to RSUs$7,611 $4,192 $1,869